BioCentury | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

...in a key leadership role focused on early development and innovation. Baskin-Bey was CMO of Innocrin Pharmaceuticals Inc....
BioCentury | Feb 23, 2017
Clinical News

Seviteronel: Ph I/II CLARITY data

...enrolling women with unresectable, locally advanced or metastatic estrogen receptor-positive or triple-negative breast cancer (TNBC). Innocrin Pharmaceuticals Inc....
...ORR) and progression-free survival (PFS) Status: Phase I/II data Milestone: Additional Phase I/II data (2017) Alex Himes VT-464 Innocrin Pharmaceuticals Inc. Androgen...
BioCentury | Oct 6, 2016
Company News

Management tracks

...of translational sciences at the California Institute for BioMedical Research (La Jolla, Calif.). Cancer play Innocrin Pharmaceuticals Inc....
BioCentury | Jun 8, 2015
Clinical News

VT-464: Phase II started

...in 28-day cycles in about 148 chemotherapy-naive patients progressing on Xtandi enzalutamide or Zytiga abiraterone. Innocrin Pharmaceuticals Inc....
BioCentury | Apr 20, 2015
Financial News

Innocrin Pharmaceuticals completes venture financing

Innocrin Pharmaceuticals Inc. , Durham, N.C. Business: Cancer Date completed: 2015-04-14 Type: Venture financing Raised: $28 million Investors: Eshelman Ventures; Novartis Venture Funds; Lilly Ventures; Hatteras Venture Partners; Intersouth Partners; A&B Equity Holdings WIR Staff...
BioCentury | Mar 16, 2015
Clinical News

VT-464: Interim Phase I/II data

...Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando. Innocrin Pharmaceuticals Inc....
BioCentury | Nov 17, 2014
Emerging Company Profile

Treating CRPC failures

...the round to $19 million. Companies and Institutions Mentioned Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Innocrin Pharmaceuticals Inc....
...of Oncology 7 1802-7 (2013) Shaffer, C. "Metallic strategy." BioCentury 15 (Nov. 3, 2014) Sidebars Innocrin Pharmaceuticals Inc....
BioCentury | Nov 10, 2014
Financial News

Innocrin Pharmaceuticals completes venture financing

Innocrin Pharmaceuticals Inc. , Durham, N.C. Business: Cancer Date completed: 2014-10-22 Type: Venture financing Raised: $14 million Investors: Novartis Option Fund; Lilly Ventures; Hatteras Funds; Intersouth Partners; Lurie Investments; Astellas Venture WIR Staff cancer...
BioCentury | Nov 3, 2014
Finance

Metallic strategy

...with the financing, Viamet said it would spin its prostate cancer assets out into newco Innocrin Pharmaceuticals Inc....
BioCentury | Oct 27, 2014
Company News

Viamet cancer, infectious news

...it will spin out its prostate cancer program to existing investors in a newco called Innocrin Pharmaceuticals...
Items per page:
1 - 10 of 11
BioCentury | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

...in a key leadership role focused on early development and innovation. Baskin-Bey was CMO of Innocrin Pharmaceuticals Inc....
BioCentury | Feb 23, 2017
Clinical News

Seviteronel: Ph I/II CLARITY data

...enrolling women with unresectable, locally advanced or metastatic estrogen receptor-positive or triple-negative breast cancer (TNBC). Innocrin Pharmaceuticals Inc....
...ORR) and progression-free survival (PFS) Status: Phase I/II data Milestone: Additional Phase I/II data (2017) Alex Himes VT-464 Innocrin Pharmaceuticals Inc. Androgen...
BioCentury | Oct 6, 2016
Company News

Management tracks

...of translational sciences at the California Institute for BioMedical Research (La Jolla, Calif.). Cancer play Innocrin Pharmaceuticals Inc....
BioCentury | Jun 8, 2015
Clinical News

VT-464: Phase II started

...in 28-day cycles in about 148 chemotherapy-naive patients progressing on Xtandi enzalutamide or Zytiga abiraterone. Innocrin Pharmaceuticals Inc....
BioCentury | Apr 20, 2015
Financial News

Innocrin Pharmaceuticals completes venture financing

Innocrin Pharmaceuticals Inc. , Durham, N.C. Business: Cancer Date completed: 2015-04-14 Type: Venture financing Raised: $28 million Investors: Eshelman Ventures; Novartis Venture Funds; Lilly Ventures; Hatteras Venture Partners; Intersouth Partners; A&B Equity Holdings WIR Staff...
BioCentury | Mar 16, 2015
Clinical News

VT-464: Interim Phase I/II data

...Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando. Innocrin Pharmaceuticals Inc....
BioCentury | Nov 17, 2014
Emerging Company Profile

Treating CRPC failures

...the round to $19 million. Companies and Institutions Mentioned Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Innocrin Pharmaceuticals Inc....
...of Oncology 7 1802-7 (2013) Shaffer, C. "Metallic strategy." BioCentury 15 (Nov. 3, 2014) Sidebars Innocrin Pharmaceuticals Inc....
BioCentury | Nov 10, 2014
Financial News

Innocrin Pharmaceuticals completes venture financing

Innocrin Pharmaceuticals Inc. , Durham, N.C. Business: Cancer Date completed: 2014-10-22 Type: Venture financing Raised: $14 million Investors: Novartis Option Fund; Lilly Ventures; Hatteras Funds; Intersouth Partners; Lurie Investments; Astellas Venture WIR Staff cancer...
BioCentury | Nov 3, 2014
Finance

Metallic strategy

...with the financing, Viamet said it would spin its prostate cancer assets out into newco Innocrin Pharmaceuticals Inc....
BioCentury | Oct 27, 2014
Company News

Viamet cancer, infectious news

...it will spin out its prostate cancer program to existing investors in a newco called Innocrin Pharmaceuticals...
Items per page:
1 - 10 of 11